The University of North Carolina at Chapel Hill (UNC), in collaboration with Duke University and the Hamner-UNC Institute for Drug Safety Sciences (IDSS), has a successful T32 training program in clinical pharmacology that builds on our exceptional research environment with world-class programs in drug discovery, drug development, pediatric clinical pharmacology, pharmacogenomics, and drug safety. We have an outstanding track record of training clinician-scientists in clinical pharmacology and an excellent and diverse applicant pool with many more qualified applicants than funded positions. Our training program detailed in this renewal application offers strong leadership, internationally-recognized mentors from multiple disciplines who are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program is derived both from MDs in medical specialty training programs seeking a career path in clinical pharmacology and PharmDs in advanced clinical/translational research training. Trainees, guided by individualized mentoring teams, complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research, from pharmacokinetics, pharmacometrics and pharmacogenomics to clinical trial design and ethics. Faculty mentors are chosen based on their research productivity in at least one of four focus areas that form the core of this training program: Drug Disposition and Action; Quantitative Pharmacology and Clinical Trial Design; Pharmacogenomics; Drug-induced Organ Toxicity. A unique feature of this training program is our focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The keen interest in clinical pharmacology within our trainee pool, the unparalleled investment in clinical pharmacology research resources at all three institutions, the intellectually-rich biomedical science environment of Research Triangle Park, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in clinical pharmacology.
There has been an explosion in understanding of the biology underlying disease and interindividual variation in drug disposition and response to pharmacotherapy. This has provided unprecedented opportunities in drug development and the individualization of therapy to treat and ultimately cure disease. The proposed program will produce diverse clinical pharmacologists that will be well-trained to lead the effort to capitalize on these great opportunities.
|Parikh, Kishan S; Fiuzat, Mona; Davis, Gordon et al. (2018) Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med 11:e002210|
|Wang, Laura A; Smith, P Brian; Laughon, Matthew et al. (2018) Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants. Early Hum Dev 125:26-30|
|Autmizguine, Julie; Melloni, Chiara; Hornik, Christoph P et al. (2018) Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children. Antimicrob Agents Chemother 62:|
|Salerno, Sara N; Burckart, Gilbert J; Huang, Shiew-Mei et al. (2018) Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities. Clin Pharmacol Ther :|
|Garrett, Katy L; Chen, Jingxian; Maas, Brian M et al. (2018) A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. J Pharmacol Exp Ther 367:245-251|
|Rivera-Chaparro, Nazario D; Ericson, Jessica; Wu, Huali et al. (2018) Safety, Effectiveness, and Exposure-Response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records. Pediatr Infect Dis J :|
|Hernandez, Michelle L; Dhingra, Radhika; Burbank, Allison J et al. (2018) Low-level ozone has both respiratory and systemic effects in African American adolescents with asthma despite asthma controller therapy. J Allergy Clin Immunol 142:1974-1977.e3|
|Ge, Shufan; Beechinor, Ryan J; Hornik, Christoph P et al. (2018) External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database. Antimicrob Agents Chemother 62:|
|Balevic, Stephen J; Cohen-Wolkowiez, Michael (2018) Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children. J Clin Pharmacol 58 Suppl 10:S58-S72|
|Dallefeld, Samantha H; Atz, Andrew M; Yogev, Ram et al. (2018) A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. J Pharmacokinet Pharmacodyn 45:419-430|
Showing the most recent 10 out of 133 publications